BioCryst Pharmaceuticals, Inc.

BMV:BCRX * Stock Report

Market Cap: Mex$32.0b

BioCryst Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BMV:BCRX * Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
24 Jun 24SellMex$980,222Amy McKeeIndividual8,600Mex$113.98
17 Jun 24SellMex$521,185A. SandersIndividual4,689Mex$111.15
14 Jun 24SellMex$754,236Theresa HeggieIndividual6,698Mex$112.61
30 May 24BuyMex$846,357Alan LevinIndividual7,861Mex$107.67
24 May 24BuyMex$267,374Stephen AselageIndividual2,500Mex$106.95
20 May 24BuyMex$1,553,634Vincent MilanoIndividual15,000Mex$103.58
20 May 24BuyMex$528,650Nancy HutsonIndividual5,000Mex$105.73
14 May 24BuyMex$3,408,718Anthony DoyleIndividual36,300Mex$93.90
14 May 24BuyMex$2,963,795Helen ThackrayIndividual30,000Mex$98.79
13 May 24BuyMex$464,755Alane BarnesIndividual5,000Mex$92.95
13 May 24BuyMex$2,758,275Charles GayerIndividual30,000Mex$91.94
13 May 24BuyMex$2,024,594Steven K. GalsonIndividual21,940Mex$92.28
13 May 24BuyMex$2,798,615Jon StonehouseIndividual30,000Mex$93.29

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of BCRX *?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,037,2020.984%
Hedge Funds11,865,0005.73%
General Public30,079,22814.5%
Institutions163,151,14178.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 64.19% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.1%
BlackRock, Inc.
20,915,971Mex$3.2b4.81%no data
10%
The Vanguard Group, Inc.
20,730,939Mex$3.2b2.09%no data
5.73%
Avoro Capital Advisors LLC
11,865,000Mex$1.8b-5.61%1.26%
4.39%
Kynam Capital Management, LP
9,085,368Mex$1.4b2.93%5.53%
4.27%
State Street Global Advisors, Inc.
8,849,588Mex$1.4b-5.32%no data
3.93%
Deerfield Management Company, L.P. Series C
8,135,804Mex$1.3b0%1.1%
2.85%
Alkeon Capital Management, LLC
5,894,274Mex$911.6m-0.1%0.31%
2.34%
Geode Capital Management, LLC
4,837,985Mex$748.3m2.71%no data
2.32%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
4,801,454Mex$742.6m6.95%0.01%
1.86%
Rp Management, Llc, Asset Management Arm
3,846,154Mex$594.9m0%13.41%
1.75%
Rock Springs Capital Management LP
3,622,358Mex$560.2m0.09%0.94%
1.61%
Fisher Asset Management, LLC
3,338,062Mex$516.3m16.9%0.01%
1.58%
GW&K Investment Management, LLC
3,277,600Mex$506.9m-3.73%0.2%
1.25%
Caligan Partners, LP
2,583,585Mex$399.6m-43.8%6.18%
1.09%
T. Rowe Price Group, Inc.
2,252,749Mex$348.4m15.6%no data
1.05%
Two Sigma Advisers, LP
2,181,012Mex$337.3m13.6%0.04%
1.04%
Rice Hall James & Associates, LLC
2,163,743Mex$334.7m4.04%0.88%
0.96%
FMR LLC
1,987,535Mex$307.4m2.33%no data
0.91%
Charles Schwab Investment Management, Inc.
1,887,994Mex$292.0m5.76%no data
0.9%
Northern Trust Global Investments
1,860,925Mex$287.8m6.05%no data
0.89%
Stifel Asset Management Corp.
1,843,289Mex$285.1m-0.02%0.01%
0.87%
Voloridge Investment Management, LLC
1,792,908Mex$277.3m-30.8%0.05%
0.86%
Columbia Management Investment Advisers, LLC
1,772,501Mex$274.1m-4.99%no data
0.85%
Two Sigma Investments, LP
1,760,808Mex$272.3m5.16%0.03%
0.81%
Goldman Sachs Group, Investment Banking and Securities Investments
1,677,332Mex$259.4m-15.5%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 12:57
End of Day Share Price 2024/11/11 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioCryst Pharmaceuticals, Inc. is covered by 30 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Tazeen AhmadBofA Global Research
Dae Gon HaBTIG